Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1048 • ACR Convergence 2021
Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
ana Perez¹, Fernando Albarran², Cristina Bohorquez², Atusa Movasat², Lucia Ruiz², Paula Pretel², elena Rabadan², Valentina Emperiale², Adrian abbasi³, julio suarez³, lorena montano³, emilio rico³, alfredo prieto⁴, Inmaculada Leon⁵, melchor Alvarez de Mon³ and beatriz perez⁶, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ³Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁴Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ⁵Communicable Diseases. Instituto de Salud Carlos III, Madrid, Spain, ⁶Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain
Background/Purpose: Classical statistics provide information on mortality rates for basic causes of death. Although many inflammatory rheumatic diseases decrease life expectancy, they are generally not…
Abstract Number: 1260 • ACR Convergence 2021
Factors That Impact Medication Adherence in Hospitalized Patients with Systemic Lupus Erythematosus
Prarthana Jain¹, Mithu Maheswaranathan², Holly Mitchell³ and Diane Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²Duke University School of Medicine, Durham, NC, ³Ralph H Johnson VA Medical Center, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by episodes of flares, often involving multiple organ systems. Medication nonadherence remains a significant problem,…
Abstract Number: 1276 • ACR Convergence 2021
Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
Manuel Ugarte-Gil¹, Guillermo Ruiz-Irastorza², Dafna Gladman³, Murray Urowitz⁴, Ann Clarke⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul R Fortin¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jnsen²³, Ronald F van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, S Sam Lim²⁶, Murat Inanc²⁷, Kenneth Kalunian²⁸, Soren Jacobsen²⁹, Christine Peschken³⁰, Diane Kamen³¹, Anca Askanase³², Bernardo A. Pons-Estel³³ and Graciela Alarcn³⁴, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹⁰Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ¹¹McGill University, Montréal, QC, Canada, ¹²Cedars-Sinai, Los Angeles, CA, ¹³Centre for Rheumatology, University College London, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Wexford, PA, ²³Lund University, Lund, Sweden, ²⁴Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁸UC San Diego, La Jolla, CA, ²⁹Rigshospitalet, Copenhagen, Denmark, ³⁰University of Manitoba, Winnipeg, MB, Canada, ³¹Medical University of South Carolina, Charleston, SC, ³²Columbia University Medical Center, New York, NY, ³³Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ³⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remission and LLDAS have been proposed as the goals for the treatment of SLE patients. However, the predictors of each state remain unknown. The…
Abstract Number: 1292 • ACR Convergence 2021
Systemic Lupus Erythematous Readmissions Has Reduced in the Last Decade in the United States: A 9- year Longitudinal Study of the Nationwide Readmission Database
Ehizogie Edigin¹, Precious Eseaton², Chinenye Osuorji³, Ajayi Temitope⁴, Oluwafeyi Adedoyin⁵, Nneka Chukwu⁶ and Augustine Manadan⁷, ¹Internal Medicine, John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin, Benin, Nigeria, ³Internal Medicine, Burrell College of Osteopathic Medicine, Las Cruces, NM, ⁴Internal Medicine, University of Buffalo, Buffalo, NY, ⁵Internal Medicine, Englewood Hospital and Medicine Center, Englewood, NJ, ⁶Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁷Rush University Medical Center, Chicago, IL
Background/Purpose: Longitudinal data on trends of Systemic Lupus Erythematous (SLE) readmissions is scarce. Our study aims to study trends of 30-day readmissions of patients admitted…
Abstract Number: 1425 • ACR Convergence 2021
Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study
Amit Saxena¹, Christopher Mela² and Antonia Coeshall³, ¹NYU School of Medicine, New York, NY, ²Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Rockville
Background/Purpose: Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in 2 pivotal trials in adult patients with lupus nephritis (LN). Previously reported results…
Abstract Number: 1484 • ACR Convergence 2021
B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, Winn Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our laboratory previously demonstrated a strong association of B cell intracellular interferon beta (IFNβ) with the development of anti-Smith/ribonuclear protein (Sm/RNP), anti-DNA, and lupus…
Abstract Number: 1504 • ACR Convergence 2021
Association Between Anti-RNP Antibodies and Interferon Gene Expression but Not Complement Consumption in SLE
Erika Hubbard¹, David Pisetsky² and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²Duke University Medical Center, Durham, NC
Background/Purpose: Anti-nuclear antibodies are important serologic features of SLE and facilitate diagnosis. Anti-double stranded DNA (dsDNA) antibodies are routinely monitored for disease prognosis and are…
Abstract Number: 1712 • ACR Convergence 2021
Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants
Julianna Sabo¹, Namrata Singh², Deborah Crane¹, David Doody³, Melissa Schiff⁴ and Beth Mueller⁵, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³Fred Hutchinson Cancer Research Center, Seattle, WA, ⁴University of Washington, University of New Mexico, Seattle, WA, ⁵Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…
Abstract Number: 1744 • ACR Convergence 2021
Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
Paramarajan Piranavan¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: The clinical heterogeneity of the SLE makes it often challenging for the treating clinician and also remains one of the many reasons behind failed…
Abstract Number: 1763 • ACR Convergence 2021
Baricitinib Reduces Proinflammatory Serum Cytokines in Patients with Systemic Lupus Erythematosus 
Thomas Dörner¹, Yoshiya Tanaka², Daniel Wallace³, Damiano Fantini⁴, Alisa Koch⁴, Maria Silk⁵, Jorge Ross Terres⁴, Jonathan Sims⁴, Peter Fischer⁶ and Michelle Petri⁷, ¹Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Cedars-Sinai, Los Angeles, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Carmel, IN, ⁶Eli Lilly and Company, North Easton, MA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Baricitinib, a Janus kinase (JAK)1/JAK2 inhibitor, improved disease activity in systemic lupus erythematosus (SLE) adults receiving standard background therapy in a phase 2 trial…
Abstract Number: 1933 • ACR Convergence 2021
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Emily Gilbert⁵, Maria Valenzuela-Almada⁶, Leanna Wise⁷, Jeffrey Sparks⁸, Tiffany Hsu⁹, Kristin D'Silva¹⁰, Naomi Patel¹⁰, Emily Sirotich¹¹, Jean Liew¹², Jonathan Hausmann¹³, Paul Sufka¹⁴, Rebecca Grainger¹⁵, Suleman Bhana¹⁶, Wendy Costello¹⁷, Zachary Wallace¹⁸, Lindsay Jacobsohn¹⁹, Anja Strangfeld²⁰, Elsa Frazão Mateus²¹, Kimme Hyrich²², Laure Gossec²³, Loreto Carmona²⁴, Saskia Lawson-Tovey²², Lianne Kearsley-Fleet²⁵, Martin Schaefer²⁶, Pedro Machado²⁷, Philip Robinson²⁸, Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Jacksonville, FL, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Boston University, Boston, MA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹⁴HealthPartners, Eagan, MN, ¹⁵University of Otago, Wellington, New Zealand, ¹⁶Crystal Run Health, Montvale, NJ, ¹⁷Irish Children's Arthritis Network, Bansha, Ireland, ¹⁸Massachusetts General Hospital, Newton, MA, ¹⁹University of California San Francisco, Antioch, CA, ²⁰Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ²¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ²²University of Manchester, Manchester, United Kingdom, ²³Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²⁴Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ²⁵Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²⁶German Rheumatism Research Center, Berlin, Germany, ²⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²⁸Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…
Abstract Number: 0077 • ACR Convergence 2021
Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus
Prarthana Jain, Jim Oates, Dulaney Wilson and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Antiphospholipid antibody (aPL) positivity is associated with elevated risk of thrombosis among patients with SLE, but other clinical associations are less well-known. The goal…
Abstract Number: 0323 • ACR Convergence 2021
Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients
Katie Liao¹, Thilinie De Silva¹, Julie Bonin², Rachel Koelmeyer² and Alberta Hoi³, ¹Department of Rheumatology, Monash Health, Melbourne, Australia, ²Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Antibodies to Ro60 (SSA) or Ro52 (SSB) have been described as one of the defining autoantibodies in Sjogren syndrome but they are also commonly…
Abstract Number: 0339 • ACR Convergence 2021
Trends in Disparity by Age, Sex and Race for Systemic Lupus Erythematosus Patients
Anum Akhlaq¹ and Abdul Mannan Khan Minhas², ¹Orange Park Medical Center, Orange Park, FL, ²Forrest General Hospital, Hattiesburg
Background/Purpose: Important disparities in SLE patients persist based on their sex and racial/ethnic status. The aim of this study is to examine the trends in…
Abstract Number: 0470 • ACR Convergence 2021
Inhibition of Toll-Like Receptor 7 (TLR7) with the Potent and Selective Inhibitor of Human TLR7 and TLR8 BMS-986256 Provides Robust Efficacy in Murine Lupus Models, Reversing Established Disease
Shailesh Dudhgaonkar¹, Anjuman Rudra¹, Sourabh Ranade¹, Siva Subramani¹, Jignesh Nagar¹, Preethi Karunanithi¹, Priyadeep Bhutani¹, Vishwanath Kurawattimath¹, Rosemary Zhang², Hongchen Qiu², ALARIC DYCKMAN² and Gary Schieven², ¹Biocon Bristol Myers Squibb Research Center, Bangalore, India, ²Bristol Myers Squibb, Lawrenceville, NJ
Background/Purpose: TLR7, a member of the Toll-Like Receptor family, recognizes ssRNA and is primarily expressed in plasmacytoid dendritic cells and B cells. TLR7 has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].